CX Institutional Buys 3,821 Shares of Johnson & Johnson (NYSE:JNJ)

CX Institutional increased its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 6.6% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 62,134 shares of the company's stock after purchasing an additional 3,821 shares during the quarter. CX Institutional's holdings in Johnson & Johnson were worth $10,304,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in JNJ. WealthTrak Capital Management LLC bought a new stake in Johnson & Johnson during the fourth quarter valued at $26,000. Mountain Hill Investment Partners Corp. purchased a new stake in Johnson & Johnson during the fourth quarter valued at about $29,000. Conquis Financial LLC purchased a new stake in Johnson & Johnson during the fourth quarter valued at about $33,000. Bernard Wealth Management Corp. purchased a new stake in Johnson & Johnson during the fourth quarter valued at about $36,000. Finally, Runnymede Capital Advisors Inc. purchased a new stake in Johnson & Johnson during the fourth quarter valued at about $38,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 0.9%

Shares of NYSE JNJ traded up $1.35 during trading hours on Thursday, hitting $156.61. The company's stock had a trading volume of 7,065,256 shares, compared to its average volume of 7,948,712. The business has a 50-day simple moving average of $153.69 and a 200-day simple moving average of $153.71. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The stock has a market cap of $376.82 billion, a price-to-earnings ratio of 23.55, a P/E/G ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. On average, analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 3.32%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's payout ratio is presently 57.84%.

Analyst Ratings Changes

A number of equities research analysts have weighed in on JNJ shares. Morgan Stanley raised their price target on Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 16th. The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their price target for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Barclays decreased their price objective on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a report on Thursday, April 17th. Royal Bank of Canada reiterated an "outperform" rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Thursday, June 5th. Finally, Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Eleven research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.